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BACKGROUND: Epigenetic silencing of Wnt antagonists and expression changes in genes associated with Wnt response pathways occur
in early sporadic colorectal tumourigenesis, indicating that tumour cells are more sensitive to Wnt growth factors and respond
differently. In this study, we have investigated whether similar changes occur in key markers of the Wnt response pathways in the
genetic form of the disease, familial adenomatous polyposis (FAP).
METHODS: We investigated epigenetic and expression changes using pyrosequencing and real-time RT-PCR in samples from seven
patients without neoplasia, and matched normal and tumour tissues from 22 sporadic adenoma and 14 FAP patients.
RESULTS: We found that 17 out of 24 (71%) FAP adenomas were hypermethylated at sFRP1, compared with 20 out of 22 (91%) of
sporadic cases. This was reflected at the level of sFRP1 transcription, where 73% of FAP and 100% of sporadic cases were down-
regulated. Increased expression levels of c-myc and FZD3 were less common in FAP (35 and 46% respectively) than sporadic tumours
(78 and 67% respectively).
CONCLUSION: Overall, the changes in expression and methylation were comparable, although the degree of change was generally
lower in the FAP adenomas. Molecular heterogeneity between multiple adenomas from individual FAP patients may reflect different
developmental fates for these premalignant tumours.
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Loss of APC gene activity is a common event in sporadic colorectal
tumourigenesis, occurring in about 80% of cases (Morin et al,
1997). Germ-line mutation of the APC gene causes familial
adenomatous polyposis (FAP) and this, along with mice carrying
similar mutations, has been investigated extensively as a paradigm
for sporadic disease (Fearnhead et al, 2001).
The majority of sporadic colorectal dysplasia and malignancy
require inactivation of the APC gene, promoting b-catenin/TCF4-
mediated transcription. Because APC functions within the Wnt/b-
catenin arm of the Wnt signalling pathway, it may be expected that
changes in these pathways and their actions associated with
tumourigenesis would be similar in both genetic and sporadic
diseases.
Previous studies have identified two further frequent Wnt
pathway changes in sporadic tumours. First, secreted Wnt
antagonists, both the sFRP family and the structurally unrelated
WIF-1, are silenced epigenetically (Caldwell et al, 2004; Suzuki
et al, 2004; He et al, 2005). These are b-catenin-responsive genes
(Caldwell et al, 2006): in the absence of epigenetic silencing, APC
mutation and consequent b-catenin action would lead to Wnt
antagonist induction in a negative feedback loop (Caldwell et al,
2008), starving the tumour cell of Wnt ligand. Because Wnt
deprivation of primary tumour cells in culture leads to apoptosis
(He et al, 2005), this silencing may be necessary for survival of the
early tumour.
The second Wnt-associated change observed in early sporadic
tumours is a re-organisation of the Wnt response pathways away
from b-catenin responses and towards the less well-characterised
b-catenin-independent outcomes (Caldwell et al, 2008). These
include changes in FZD receptor profiles and high-level induction
of NKD1, which effectively diverts Wnt ligand-derived signals
away from b-catenin and towards Wnt/PCP outcomes (Yan et al,
2001). In normal epithelia, these changes most likely represent
transient negative feedback responses that desensitise the cell to
high levels of Wnt ligands but their sustained expression in
tumour cells may contribute to the tumourigenic process.
Although the spectrum of outcomes has yet to be characterised,
one result of Wnt/PCP signalling is c-jun phosphorylation, an
essential step in colorectal tumourigenesis (Nateri et al, 2005).
Studies in FAP tissues and Apc
min mice could advance our
understanding of the Wnt pathway changes observed in sporadic
tumours. A number of studies using tissue from FAP patients have
failed to show nuclear localisation of b-catenin in early adenomas
with mild dysplasia, unlike sporadic adenomas (Anderson et al,
2002; Bla ¨ker et al, 2003; Phelps et al, 2009), which raises questions
about the sequence of events following APC loss in FAP.
Interestingly a recent article by Obrador-Hevia et al (2010)
showed increased nuclear staining of b-catenin in FAP adenomas
which correlated with larger size (adenomas 41cm) and biallelic
APC inactivation. Early changes in Wnt signalling pathways may
provide targets for cancer prevention. A similar profile of changes
must occur in FAP for it to be used as a model system to evaluate
such therapies. Similarly, differences in changes in the Wnt
signalling components between sporadic and genetic disease may
further our understanding of the key mutational events in the
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sdevelopment of this common tumour. We therefore set out to
examine key components of the Wnt signalling pathways in FAP
adenomas and compare any alterations with those found in
sporadic cases.
MATERIALS AND METHODS
Patient samples
Sporadic adenoma samples were identified from our tumour bank
from patients more than 50 years of age and without a family
history of colorectal cancer. All tumour samples were collected
from the sigmoid colon or the rectum and matched control rectal
biopsies were taken at the same procedure (5cm or more from the
tumour site). Familial adenomatous polyposis adenoma and
matched control samples were taken from patients with a proven
diagnosis of FAP. Normal unaffected control samples were taken
from patients with no gastrointestinal malignancy. A summary of
the clinical characteristics of each sample group can be found in
Table 1. Samples were collected according to local ethical
committee regulations, with individual consent from each patient
for molecular studies.
Quantitative real-time RT-PCR
Total RNA was extracted from the patient samples using TRI
Reagent (Sigma, Poole, UK) and 0.5mg total RNA was converted
to cDNA using a High Capacity cDNA Reverse Transcription
Kit (Applera, Warrington, UK). Oligonucleotide primers and
TaqMan probe sequences are shown in Tables 1 and 2. Multiplex
polymerase chain reaction (PCR) amplifications were performed
using an ABI PRISM 7500 Sequence Detector (Warrington,
Table 1 Summary of the clinical features of the three sample groups (normal unaffected, sporadic disease and FAP patients)
Sample group Sex (M/F)
Median age
in years (range)
Total
biopsy no.
Site of biopsy –
right/left side
of colon (ND)
Median size of adenoma
in mm (range)
Pathology
(TA/TVA)
Grade of dysplasia
(low/high)
Normal 6/1 60 (35–68) 12 control 1/11 — — —
Unaffected — — — — —
Sporadic 12/10 65 (56–79) 22 control 0/22 — — —
Disease 22 adenoma 1/21 10 (5–30) 10/12 19/3
FAP patients 9/9 24 (18–38) 18 control 9/7 (6) — — —
30 adenoma 9/15 (6) 5 (2–35) 29/1 29/1
Abbreviations: M¼male; F¼female; TA¼tubular adenoma; ND¼not documented; TVA¼tubular villus adenoma. Right-sided adenomas are taken between the rectum and
splenic flexure, left-sided adenomas are from the transverse colon to the caecum.
Table 2 Detailed information on the FAP adenoma samples used in the methylation and expression analyses
FAP adenoma Expr Meth Sex M/F
Age in
years
Site of biopsy – right/left
side of colon (ND)
Size of
adenoma (mm)
Pathology
(TA/TVA)
Grade of dysplasia
(low/high)
1a Y Y F 32 L 2 TA Low
1b Y Y L 2 TA Low
1c Y Y L 2 TA Low
1d Y Y L 2 TA Low
2a Y N F 29 R 5 TA Low
2b Y N L 5 TA Low
2c Y N L 5 TA Low
3a Y Y M 20 L 5 TA Low
3b Y Y R 5 TVA High
3c Y Y L 35 TA Low
4a Y N F 26 R 6 TA Low
4b Y N L 9 TA Low
5a Y Y F 26 R 3 TA Low
5b Y Y R 3 TA Low
6a Y N M 21 ND 2 TA Low
7a Y Y F 23 ND 5 TA Low
8a Y Y M 20 ND 3 TA Low
9a Y Y M 19 R 5 TA Low
10a Y Y M 19 ND 3 TA Low
11a Y Y F 36 R 2 TA Low
11b Y Y R 2 TA Low
11c Y Y L 2 TA Low
11d Y Y L 3 TA Low
12a Y Y M 38 L 2 TA Low
13a Y Y F 27 ND 5 TA Low
14a Y Y F 35 L 10 TA Low
15 N Y F 25 ND 5 TA Low
16 N Y M 18 L 10 TA Low
17 N Y M 18 R 5 TA Low
18 N Y M 19 L 7 TA Low
Abbreviations: ND¼not documented; FAP¼familial adenomatous polyposis; Expr¼mRNA expression analysis performed; Meth¼methylation analysis performed; M¼male;
F¼female; TA¼tubular adenoma; TVA¼tubular villus adenoma.
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sCheshire, UK) in a final volume of 15ml. Each reaction contained
1  qPCR Mastermix (Eurogentec, Aylesbury, UK), 90nM KRT8
and target gene primers, 150nM target gene TaqMan probe, and
175nM KRT8 TaqMan probe and 1ml of cDNA. Cycling conditions
were an initial step at 501C for 2min and 951C for 10min, followed
by 40 cycles at 951C for 15s and 601C for 1min. Results from the
human target genes were normalised to the epithelial-cell-specific
gene keratin 8 (KRT8) (Table 3).
Analysis of DNA methylation status using bisulphite/
pyrosequencing
Bisulphite treatment of 1mg genomic DNA was carried out using
the EpiTect Bisulfite Kit (Qiagen, Crawley, UK) following the
manufacturer’s recommendations. Primers adapted from the
sFRP1 combined bisulphite restriction analysis (COBRA) assay
previously described by our laboratory (Caldwell et al, 2004) were
used to amplify 1ml of bisulphite-treated DNA. The primary PCR
reaction product was diluted 100-fold and 1ml of this was added to
a5 0 ml reaction containing 10pmol COBRA-F primer and 5pmol
biotin-labelled COBRA-Rnest. Each reaction was amplified using a
touchdown PCR; 941C for 3min; 20 cycles of 941C for 10s,
66–0.51C for 20s, 721C for 30s; 20 cycles of 941C for 10s, 561C for
20s, 721C for 30s and finally 721C for 5min. After PCR, the
products were captured on streptavidin-coated beads and in-
cubated with 10pmol of sequencing primer (COBRA-Fnest).
Pyrosequencing was performed using PyroMark Gold Q96 reagents
and a PyroMark Q96 MD pyrosequencing machine (Qiagen). This
assay measures the methylation status of seven CpG sites at
positions þ318, þ321, þ344, þ351, þ353, þ357 and þ370
relative to the sFRP1 translation start site. CpG sites were
hypermethylated if methylation was greater than 63%, this cut-
off value corresponds to the average methylation in normal tissue
þ2 times the standard deviation (s.d.) as described previously
(Chung et al, 2008).
Immunohistochemistry
The streptavidin–biotin indirect immunoperoxidase method was
performed as described previously (Hardy et al, 2002). Sections
(5mm) were dewaxed and re-hydrated, then endogenous perox-
idase activity was blocked by incubation with 10% H2O2 in
methanol for 30min. Microwave antigen-retrieval was undertaken
for both antibodies. Sections were incubated overnight with a
primary antibody recognising phospho-c-jun (ser63-P; Santa Cruz
Biotechnology, Heidelberg, Germany) at a dilution of 1:400,
diluted in 20% normal goat serum. After washing with PBS,
sections were incubated with biotinylated goat anti-mouse/rabbit
IgG (Dako, Ely, UK) according to the manufacturer’s instructions
for 30min. Serial PBS washing and incubation with streptavidin–
peroxidase conjugate (Dako) was undertaken before incubation
with diaminobenzidine tetrahydrochloride (Sigma-Aldrich,
Gillingham, UK). Sections were counterstained with haematoxylin
(BDH Laboratory Supplies, Poole, UK), dehydrated and analysed
on a light microscope.
Statistical methods
Wilcoxon’s signed-rank test was performed using R (http://www.
r-project.org/). P-values o0.05 were considered as significant.
Pearson’s correlation coefficient (r) was calculated as a measure of
the strength of the association between the two continuous
variables. An r value 40.7 was considered statistically significant.
RESULTS
Methylation status of sFRP1 promoter
Our previous studies have shown hypermethylation of the sFRP1
gene at the earliest stages of sporadic colorectal tumourigenesis
(Caldwell et al, 2006). To determine whether hypermethylation of
sFRP1 occurs in the large bowel mucosa and adenomas in FAP, we
measured the methylation status of seven CpG sites close to the
transcription start site of sFRP1. Samples from 14 patients with
FAP (21 normal colon mucosa and 24 adenomas), 22 patients with
sporadic adenomas (22 normal colon mucosa and 22 adenomas)
and 7 patients without large bowel neoplasia (11 normal colon
mucosa) were examined by bisulphite pyrosequencing. These
results are summarised in Figure 1.
An average methylation score for each CpG site was calculated
for the FAP patients where multiple control and adenoma samples
were available (Table 2). Analysis of the data using the Wilcoxon’s
signed-rank test shows that sFRP1 is significantly more methylated
in adenoma compared with matched normal colonic mucosa in
both FAP and sporadic patients (Table 4). The data show that
while significant methylation changes occur at CpG sites 3 and 4 in
FAP (P¼0.03), they occur at all seven sites in sporadic disease
(P¼0.003).
Normal colonic mucosa from healthy controls and patients with
sporadic disease was found to have a comparable degree of
methylation, with only small differences observed between
individual CpG sites (Figure 1). Only 1 out of 11 normal control
samples showed methylation above 63% (black circle) and in only
1 out of the 7 CpG sites. In contrast, 10 out of 21 of the normal
Table 3 Sequences of primers used in real-time RT-PCR analysis
Assay type Primers
Human PCR assays
sFRP1 (NM_003012) TaqMan F, 50-CCAATCCCACCGAAGCCT-30
R, 50-ATGATGGCCTCAGATTTCAACTC-30
P, 50-CAAGCCCCAAGGCACAACGGTG-30
NKD1 (NM_033119) TaqMan F, 50-TCGCCGGGATAGAAAACTACA-30
R, 50-CAGTTCTGACTTCTGGGCCAC-30
P, 50-CCAATTTGGGCCTGGCTCCCC-30
FZD3 (NM_017412) TaqMan F, 50-CATGGAGATGTTTGGTGTTCCTT-30
R, 50-AAGTCGAGGATATGGCTCATCAC-30
P, 50-TCTGGGAACCTACTGCATTCCATATCTTCAGG-30
c-myc (NM_002467) TaqMan F, 50-AGCTGCTTAGACGCTGGATTTT-30
R, 50-TTCCTGTTGGTGAAGCTAACGTT-30
P, 50-CAGCCTCCCGCGACGATGC-30
KRT8 (NM_002273) TaqMan F, 50-GATCGCCACCTACAGGAAGCT-30
R, 50-ACTCATGTTCTGCATCCCAGACT-30
P, 50-CCGGCTCTCCTCGCCCTCCA-30
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44%     48%       8%
55%     28%     17%
1
Key
41%     34%     25%
10%     39%     51%
0–33%
34–62%
63–100%
Sporadic adenoma
FAP mucosa
Normals
Sporadic mucosa
FAP adenoma
7 6 5 4 3 2
Figure 1 Bisulphite-pyrosequencing analysis of sFRP1 gene methylation. (A) Pictorial representation of the percentage methylation of seven CpG sites
within the first exon of the sFRP1 gene. The average methylation in normal tissue was calculated as 33%, CpG sites with less than 33% methylation are shown
as white circles. Fully methylated (above the cut-off) samples corresponded to average methylation in normal tissue þ 2 times the standard deviation (s.d.)
as described previously (Chung et al, 2008), these are shown as black circles (463% methylation). Grey circles represent 34–62% methylation. Five sample
groups are represented (normal unaffected samples (green), FAP normal mucosa (red), sporadic normal mucosa (yellow), FAP adenomas (blue) and
sporadic adenomas (purple)). The FAP normal tissue shows an increase in methylation (more black circles) compared with unaffected and sporadic normal
tissue. Both FAP and sporadic adenomas had increased methylation compared with the normal samples. (B) The table summarises the data in panel A as the
percentage number of samples within each group with methylation 0–33% (white), 34–62% (grey) and 463% (black).
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scolon samples from FAP patients show methylation of 63% or
greater at one or more CpG sites.
Adenoma samples from both FAP and sporadic patients showed
increased methylation compared with matched normal mucosa.
The sporadic adenomas showed the greatest degree of methylation.
90% of the CpG sites examined in sporadic adenomas were
methylated compared with 59% in the FAP adenomas. This is
particularly striking when examining the median methylation
value for each CpG site (data not shown). The sporadic adenomas
range from 51 to 70% methylation compared with a range of 25 to
61% methylation in the FAP adenomas. The data showed a greater
level of methylation in FAP adenomas compared with matched
normal mucosal biopsies at all CpG sites examined showing that
methylation is a frequent and early event in FAP tumourigenesis
although at a lower level than that observed in sporadic disease.
mRNA expression profile of the Wnt antagonist sFRP1
Our previous studies identified loss of sFRP1 expression at the
premalignant stage of colorectal cancer development (Caldwell
et al, 2006). To assess whether this is also seen in FAP-related
tumourigenesis and whether the epigenetic changes identified in
FAP were influencing expression, we measured mRNA levels using
quantitative real-time RT-PCR. In total 26 adenomas taken from a
cohort of 14 FAP patients aged between 18 and 38 years, and 9
sporadic adenomas taken from patients aged between 59 and 65
years were analysed. In each case the adenoma expression levels
were compared with expression levels in normal bowel mucosa
taken from the same patient as previously described (Caldwell
et al, 2004). The results are summarised in Figure 2.
Both the FAP and sporadic adenomas showed a similar trend of
down-regulation of sFRP1 expression. Of 26, 19 (73%) FAP
adenomas and all of the sporadic adenomas showed a greater
than 4-fold down-regulation of sFRP1. The magnitude of change
was different, with sporadic adenomas showing greater down-
regulation (median –973-fold, IQR  263 to  2990) than the FAP
adenomas (median  7.2-fold, IQR  3t o 44).
The widespread down-regulation of sFRP1 in FAP cases
corresponds with the epigenetic changes in sporadic adenomas
in this and our previous study. The level of sFRP1 methylation
observed in FAP and sporadic adenomas reflects the degree of
suppression of sFRP1 expression, indicating it is causative. These
data show epigenetic suppression of sFRP1 to be a common and
early event and are consistent with this being a requirement for the
development of FAP and sporadic large bowel neoplasia.
mRNA expression profile of b-catenin transcription target
genes, NKD1 and c-myc
To assess whether the sFRP1 changes in FAP and sporadic colorectal
adenomas reflected a modification of b-catenin transcriptional
activity, we measured the expression levels of two b-catenin target
genes, NKD1 and c-myc, using quantitative real-time RT-PCR.
NKD1 expression was up-regulated (44-fold) in 19 out of
26 FAP adenomas and all 9 sporadic adenomas. The magnitude of
up-regulation differed between the groups with sporadic adenomas
showing nearly a 20-fold greater effect (Figure 2). A reduction in
NKD1 expression was observed in two FAP adenomas (2a and 6a)
compared with their matched normal tissue.
c-myc was up-regulated (44-fold) in 7 out of 9 (78%) sporadic
adenomas and 9 out of 26 (35%) FAP adenomas. The nine FAP
adenomas with increased c-myc also had increased levels of NKD1.
In FAP sample 1a and 11c and sporadic samples 1 and 7, c-myc
levels are reduced whereas NKD1 is induced, suggesting other
factors may be affecting c-myc expression.
Evidence of Wnt pathway re-organisation in FAP
adenomas
FZD3 induction Our recent study (Caldwell et al, 2008) showed
that Wnt response pathways are re-organised in early colorectal
tumourigenesis: NKD1 induction is accompanied by up-regulation
of the b-catenin-independent receptors FZD3 and 6. Unlike NKD1,
however, FZD3/6 do not respond to stabilisation of b-catenin
in vitro and require a Wnt ligand signal. FZD3/6 may, therefore,
provide an indication of the degree of Wnt ligand signalling in the
tumour.
We therefore measured FZD transcript levels in the two series of
adenomas. Figure 2 shows that FZD3 was induced by a factor of
44 in 6 of 9 sporadic adenomas and 12 of the 26 FAP specimens,
suggesting a broadly similar incidence of Wnt response pathway
re-organisation between the two groups.
The inter-quartile ranges of FZD3 induction in the sporadic and
FAP adenoma groups (3–17 vs 1.0–26) showed much greater
similarity than a similar comparison for NKD1 (79–1053 vs 2–62).
An interesting observation in this study was the different
expression profiles between different adenomas taken from the
same FAP patient (see patients 1, 2 and 11, Figure 2). In sporadic
adenomas the down-regulation of sFRP1 correlates directly with an
up-regulation of NKD1, but this is not always the case in the FAP
adenomas. For instance in adenomas 2a and 6a sFRP1 and NKD1
are both down-regulated and in adenoma 8a sFRP1 is down-
regulated but there is no change in NKD1 expression.
c-jun phosphorylation We previously reported a correlation
between Wnt response pathway re-organisation and phosphoryla-
tion of c-jun, an outcome of Wnt/PCP signalling, in sporadic
adenomas (Caldwell et al, 2008). To investigate whether this occurs
in FAP, we stained paraffin sections from 11 of the FAP patients to
analyse for nuclear phosphorylated c-jun and examples of this are
shown in Figure 3. Adenomas from these patients had also been
analysed for mRNA expression of b-catenin transcription target
genes (sFRP1, NKD1 and c-myc) and the FZD3 receptor.
Nuclear phospho-c-jun was observed in the majority, 9 out of 11
FAP adenomas. Fresh frozen tissue was available for mRNA
analysis in the two FAP patient samples (patients 5 and 12), which
stained negative for nuclear phospho-c-jun. Interestingly, patient
12 showed no change in sFRP1 expression but did demonstrate
induction of NKD1, c-myc and FZD3. Patient 5 showed a more
typical molecular profile, that is, down-regulation of sFRP1 and
up-regulation of NKD1 and FZD3 although c-myc was unchanged.
This suggests that in FAP, Wnt/PCP signalling is not the only
factor involved in c-jun activation.
DISCUSSION
These data show considerable similarity between expression of
Wnt components measured in premalignant sporadic and FAP
Table 4 P-values (Wilcoxon’s rank-sum test) of methylation at each of
the seven CpG sites tested in sFRP1 in adenoma vs matched normal
mucosa in both FAP and sporadic patients
CpG site FAP (n¼14) Sporadic (n¼19)
1 0.217 0.007
2 0.367 0.006
3 0.075 0.007
4 0.096 0.016
5 0.451 0.005
6 0.975 0.016
7 0.221 0.015
Average of site 3 and 4 0.030 0.010
Average of site 1 to 7 0.119 0.003
Abbreviation: FAP¼familial adenomatous polyposis.
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slarge bowel adenomas. We have presented evidence to suggest the
magnitude of these events may be greater in sporadic disease.
These results are consistent with these changes involved in
neoplastic development and/or stabilisation.
Age-related methylation of sFRP1 has been reported (Konishi
et al, 2007). One clear distinction between sporadic and FAP
tumours is the age of the host: all the sporadic adenomas in this
study were from patients more than 56 years of age whereas FAP
adenomas were collected from colonectomies performed on
patients between 18 and 38 years of age. The impact of these age
differences on rates of APC mutation and somatic hypermethyla-
tion is difficult to estimate: if methylation were purely stochastic, it
would be reasonable to expect it to have a greater impact in older
hosts, however in this study we have shown hypermethylation in
tissue from a young population, which have been associated with
the development of neoplasia. Interestingly 17% of the CpG sites in
the younger FAP normal samples were fully methylated compared
with 8% in sporadic and only 1% in unaffected normal samples
(Figure 1B). It is possible that this is a result of contamination due
to the difficulty in sampling ‘normal’ colonic mucosa from FAP
patients but a recent report by Obrador-Hevia et al (2010) showed
abnormal expression of c-myc and repression of sFRP1 in
macroscopically normal mucosa in patients with FAP, suggesting
Wnt signalling pathway changes occur very early in FAP-
associated tumourigenesis.
Most FAP adenomas showed qualitative changes that were
similar to sporadic tumours. In those cases where b-catenin target
genes were up-regulated, the degree of induction was comparable
to that observed in sporadic adenomas, but the degree of sFRP1
suppression in FAP adenomas was smaller than in sporadic cases.
This could be the result of pre-existing change in the matched
normal mucosa, but the raw DCt data (not shown) do not indicate
this. Although sFRP1 gene hypermethylation is normally asso-
ciated with complete silencing in sporadic adenomas, the lower
levels of methylation observed in FAP adenomas appear to reflect
partial suppression of gene expression. The outcome of this, or
whatever other mechanisms are involved, is that FAP adenomas
show significant reductions in sFRP1 transcription compared with
matched normal mucosa, despite their elevated b-catenin activity.
If Wnt ligand signalling is required for adenoma formation, it may
sFRP1
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Figure 2 Real-time RT-PCR quantitation of relative mRNA expression in a series of 26 matched colorectal FAP tumours and 9 matched sporadic
colorectal tumours according to the comparative CT method as previously described (Caldwell et al, 2004). The inset shows the median and inter-quartile
ranges (IQR) of expression levels for each gene in FAP/sporadic adenomas. A, sFRP1; B, NKD1; C, c-myc; D, FZD3. The sample numbers correspond to
individual FAP patients and details of each adenoma can be found in Table 2.
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antagonists to a level at or below that found in the normal mucosa:
although the dominant mechanism for this in sporadic disease is
complete silencing, the strong genetic drive of FAP selects for
partial suppression. This is likely to be modulated by the
distribution of histone marks around the locus (McGarvey et al,
2008) and will require examination in a separate study.
Investigating the outcome of b-catenin-independent Wnt
signalling in these tumours could show whether similar outcomes
are achieved in sporadic and FAP adenomas. No unambiguous
markers of these signals have yet been identified in colorectal
tumours but a possible response is phosphorylation of c-jun,
which can be the result of b-catenin-independent Wnt signalling in
other systems. We have previously reported a correlation between
sFRP1 silencing, NKD1 expression and c-jun phosphorylation
(Caldwell et al, 2008). In this study, we again found widespread
phosphorylation (and nuclear localisation) of c-jun in FAP
adenomas and in the cases that showed the highest levels of
sFRP1 suppression. FAP adenomas have increased cytoplasmic
b-catenin compared with surrounding normal tissue but lack
nuclear b-catenin (Bla ¨ker et al, 2003; Phelps et al, 2009; Anderson
et al, 2002; this study). Phelps et al (2009) suggest a model wherein
APC loss alone stabilises the levels of cytoplasmic b-catenin and
that subsequent stabilisation and nuclear accumulation of
b-catenin occurs following other secondary events, one of which
may be c-jun phosphorylation. did not detect phospho-c-Jun (an
indicator of JNK activity) in early adenomatous tissue from FAP
patients. This contrasts with our findings where 9 out of 11 FAP
adenomas stained positive for nuclear phospho-c-jun. Adenomas
from these 11 FAP patients were available for mRNA expression
analysis and showed elevated levels of the b-catenin target gene
NKD1 indicating increased b-catenin-activated transcription.
Cowling et al (2007) showed that c-myc expression led to a
degree of sFRP1 repression in vitro. If this were the case in
colorectal tumourigenesis, we might expect a negative correlation
between sFRP1 mRNA and c-myc mRNA in this study. Pearson’s
correlation analysis of the FAP cohort shows a significant
correlation coefficient of 0.78 between sFRP1 down-regulation
and NKD1 up-regulation, but there is little correlation between
sFRP1 and c-myc levels (r¼0.098), indicating that c-myc does not
have a major role in suppression of sFRP1 in these adenomas.
Interestingly, Pearson’s correlation analysis showed a significant
positive correlation coefficient of 0.96 between c-myc and FZD3
up-regulation in the FAP series, suggesting that these genes are
under similar transcriptional control, which may be the result of
Wnt signalling rather than simply b-catenin stabilisation (Caldwell
et al, 2008).
We know that not all adenomas will become cancers and it may
be that the molecular heterogeneity we observe in FAP adenomas
represents the distinction between adenomas that are more or less
likely to become invasive tumours. It is equally possible that, as
FAP patients have a large number of adenomas, the heterogeneity
represents different stages of adenoma development. The results of
our studies however support sFRP1 suppression being an early
event in tumourigenesis, as it occurs even in FAP adenomas of
3mm or less.
We have shown that most FAP adenomas share the changes in
expression of Wnt pathway components that occur in sporadic
disease but show a greater degree of heterogeneity, even within a
single individual. Although the significance of this is as yet
unclear, it may well have an impact on the sensitivity of a subset of
tumours to targeted chemopreventive agents. These features could
be characterised prospectively in resistant tumours in clinical trials
of novel agents.
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Figure 3 Immunohistochemistry results for phospho-c-jun in FAP adenoma sections. Panels A and B show the typical pattern of nuclear staining
for phospho-c-jun in adenomas. The table summarises the mRNA expression data for each of the nuclear phospho-c-jun-positive and -negative samples
(D, down-regulation; U, up-regulation; N, no change). The relative expression values are calculated by comparing gene expression in adenoma tissue
with expression in matched normal mucosa.
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